U.S. Stem Cell, Inc. (USRM)
Stock Price:
$0.0060 USD
-0.0020 (-25.00%)
Updated Oct 22, 2020 2:16 PM EDT - Market closed
Key Info
| Market Cap |
2.44M |
| Revenue (ttm) |
4.43M |
| Net Income (ttm) |
-3.60M |
| Shares Out |
407.11M |
| EPS (ttm) |
-0.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$0.0060 |
| Previous Close |
$0.0080 |
| Change ($) |
-0.0020 |
| Change (%) |
-25.00% |
| Day's Open |
0.0080 |
| Day's Range |
0.0056 - 0.0080 |
| Day's Volume |
962,997 |
| 52-Week Range |
0.003 - 0.017 |
More Stats
| Market Cap |
2.44M |
| Enterprise Value |
8.63M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
407.11M |
| Float |
369.66M |
| EPS (basic) |
-0.01 |
| EPS (diluted) |
-0.01 |
| FCF / Share |
0.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
2.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.55 |
| PB Ratio |
n/a |
| Revenue |
4.43M |
| Operating Income |
-2.58M |
| Net Income |
-3.60M |
| Free Cash Flow |
-965,914 |
| Net Cash |
-6.19M |
| Net Cash / Share |
-0.02 |
| Gross Margin |
103.69% |
| Operating Margin |
-58.22% |
| Profit Margin |
-81.40% |
| FCF Margin |
-21.82% |
| ROA |
-95.37% |
| ROE |
n/a |
| ROIC |
183.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 6.70 | 5.52 | 3.08 | 2.19 | 2.06 | - |
| Revenue Growth | 21.38% | 79.05% | 40.71% | 6.58% | - | - |
| Gross Profit | 4.59 | 3.64 | 2.11 | 1.22 | 1.21 | - |
| Operating Income | -1.10 | -0.80 | -1.16 | -2.61 | -3.53 | - |
| Net Income | -2.16 | -3.48 | -2.07 | -1.64 | -2.25 | - |
| Shares Outstanding | 366 | 309 | 24.15 | 0.91 | 0.49 | - |
| Earnings Per Share | -0.01 | -0.01 | -0.09 | -1.80 | -4.61 | - |
| Operating Cash Flow | 0.60 | 1.23 | 0.11 | -0.84 | -1.11 | -1.91 |
| Capital Expenditures | - | 0.40 | -0.01 | - | -0.01 | -0.01 |
| Free Cash Flow | 0.60 | 1.63 | 0.10 | -0.85 | -1.12 | -1.92 |
| Cash & Equivalents | 1.37 | 1.00 | 0.28 | 0.07 | 0.05 | - |
| Total Debt | 5.24 | 5.48 | 5.26 | 4.65 | 5.41 | - |
| Net Cash / Debt | -3.87 | -4.48 | -4.98 | -4.58 | -5.37 | - |
| Assets | 1.82 | 1.60 | 0.43 | 0.23 | 0.20 | - |
| Liabilities | 8.70 | 8.70 | 8.45 | 7.95 | 11.10 | - |
| Book Value | -6.88 | -7.10 | -8.02 | -7.72 | -10.89 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
U.S. Stem Cell, Inc. |
| Country |
United States |
| Employees |
10 |
| CEO |
Miguel Tomás |
Stock Information
| Ticker Symbol |
USRM |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: USRM |
| IPO Date |
February 15, 2008 |
Description
U.S. Stem Cell, a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is based in Sunrise, Florida.